Faeth Therapeutics
FTH
24.92
-1.97
-7.33%
Faeth Therapeutics
US · FTH
#3576 by market cap
Listed 2021
24.92
-1.97
-7.33%
Live - 5344 symbols - heartbeat 219s ago
· 2026-10-08 08:56
Pre-market
24.87
-0.20%
After-hours
24.92
0.00%
- Market cap
- 643.94M
- P/E (TTM)i
- -0.41
- P/Bi
- 3.72
- EPSi
- -16.72
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on FTH?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.51M | 4.09M | 7.53M | 15.82M | 19.81M | 18.77M | 13.04M | 11.33M |
| Research & development | 8.23M | 8.35M | 11.19M | 21.66M | 30.38M | 18.30M | 18.63M | 10.96M |
| Operating profit | -12.74M | -12.44M | -18.71M | -37.48M | -50.19M | -37.06M | -31.66M | -22.29M |
| Pretax profit | -13.04M | -16.74M | -20.10M | -36.79M | -48.59M | -34.10M | -30.16M | -21.09M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -13.04M | -16.74M | -20.10M | -36.79M | -48.59M | -34.10M | -30.16M | -21.09M |
| Basic EPS | -492 | -33 | -14 | -27 | -32 | -24 | -24 | -17 |
| Diluted EPS | -491.65 | -33.36 | -13.67 | -26.60 | -31.60 | -24.40 | -24.01 | -16.72 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.55M | 2.67M | 2.32M | 2.79M | 19.71M | 9.21M |
| Research & development | 3.73M | 2.53M | 2.54M | 2.17M | 150.91M | 9.18M |
| Operating profit | -7.27M | -5.21M | -4.85M | -4.96M | -170.63M | -18.39M |
| Pretax profit | -6.86M | -4.94M | -4.57M | -4.72M | -170.24M | -16.01M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -6.86M | -4.94M | -4.57M | -4.72M | -170.24M | -16.01M |
| Basic EPS | -5 | -4 | -4 | -4 | -131 | -3 |
| Diluted EPS | -5.45 | -3.91 | -3.62 | -3.74 | -131.45 | -2.84 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.28M | 502.00K | 20.08M | 148.54M | 108.59M | 67.25M | 41.93M | 21.51M |
| Cash & ST investments | 653.00K | 251.00K | 16.60M | 147.62M | 107.12M | 65.76M | 41.34M | 21.18M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.85M | 1.22M | 21.43M | 153.23M | 118.38M | 74.37M | 45.36M | 22.90M |
| Total current liabilities | 2.66M | 21.71M | 4.83M | 4.89M | 9.07M | 5.64M | 5.45M | 4.25M |
| Short-term debt | 696.00K | 16.06M | 32.00K | 680.00K | 2.13M | 2.44M | 2.32M | 1.45M |
| Long-term debt | 4.05M | -- | 567.00K | -- | -- | -- | -- | -- |
| Total liabilities | 55,330,000.00 | 69,879,000.00 | 77,871,000.00 | 6,712,000.00 | 14,968,000.00 | 9,479,000.00 | 6,975,000.00 | 4,310,000.00 |
| Total equity | -53.48M | -68.66M | -56.44M | 146.51M | 103.41M | 64.90M | 38.39M | 18.59M |
| Retained earnings | -75.57M | -92.31M | -112.41M | -149.21M | -197.79M | -231.90M | -262.05M | -283.14M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 35.68M | 29.57M | 25.79M | 21.51M | 204.23M | 188.66M |
| Cash & ST investments | 34.33M | 28.63M | 25.04M | 21.18M | 202.79M | 186.44M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 38.27M | 31.78M | 27.59M | 22.90M | 205.38M | 189.31M |
| Total current liabilities | 5.23M | 3.87M | 4.44M | 4.25M | 14.19M | 9.58M |
| Short-term debt | 2.15M | 1.96M | 1.88M | 1.45M | 1.04M | 592.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 6,286,000.00 | 4,469,000.00 | 4,582,000.00 | 4,310,000.00 | 342,667,000.00 | 16,348,000.00 |
| Total equity | 31.99M | 27.31M | 23.01M | 18.59M | -137.29M | 172.96M |
| Retained earnings | -268.92M | -273.85M | -278.42M | -283.14M | -453.37M | -469.38M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.31M | -8.57M | -17.71M | -30.26M | -39.03M | -32.02M | -24.67M | -20.45M |
| Depreciation & amortization | 44.00K | 73.00K | 209.00K | 685.00K | 1.35M | 1.35M | 1.32M | 139.00K |
| Free cash flow | -10.34M | -8.62M | -18.91M | -32.29M | -39.35M | -32.20M | -24.82M | -20.47M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 140.59M | 0 | -10.38M | 0 | -1.00K |
| Ending cash balance | 653.00K | 251.00K | 16.60M | 7.16M | 17.80M | 13.01M | 9.99M | 8.67M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -7.09M | -5.91M | -3.59M | -3.86M | -10.73M | -15.67M |
| Depreciation & amortization | 34.00K | 37.00K | 34.00K | 34.00K | 30.00K | 25.00K |
| Free cash flow | -7.09M | -5.93M | -3.59M | -3.86M | -10.74M | -15.67M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 9.88M | 12.56M | 10.56M | 8.67M | 152.33M | 26.90M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -81.70 | -38.88 | -40.52 | -58.40 | -74.01 |
| ROA %i | -910.43 | -1,339.68 | -178.44 | -42.13 | -35.78 | -35.38 | -50.37 | -61.78 |
| ROIC %i | -- | -- | -- | -78.84 | -38.53 | -41.18 | -57.56 | -71.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -58.70 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.48 | 0.02 | 4.16 | 30.38 | 11.98 | 11.92 | 7.70 | 5.06 |
| Quick ratioi | 0.25 | 0.01 | 3.44 | 30.19 | 11.82 | 11.65 | 7.59 | 4.98 |
| Debt / assetsi | 256.54 | 1,319.23 | 3.20 | 1.54 | 6.79 | 8.35 | 8.48 | 6.59 |
| LT debt / equityi | -- | -- | -- | 1.14 | 5.71 | 5.81 | 3.98 | 0.32 |
| Interest coveragei | -38.87 | -6.42 | -10.90 | -53.92 | -220.86 | -235.81 | -334.08 | -657.91 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -64.18 | -67.47 | -70.18 | -74.01 | -- | -195.26 |
| ROA %i | -55.31 | -58.58 | -59.72 | -61.78 | -151.41 | -176.88 |
| ROIC %i | -62.72 | -65.67 | -68.10 | -71.53 | -- | -195.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.82 | 7.64 | 5.81 | 5.06 | 14.39 | 19.69 |
| Quick ratioi | 6.57 | 7.39 | 5.64 | 4.98 | 14.29 | 19.46 |
| Debt / assetsi | 8.38 | 8.05 | 7.33 | 6.59 | 0.51 | 0.31 |
| LT debt / equityi | 3.30 | 2.18 | 0.63 | 0.32 | -- | -- |
| Interest coveragei | -386.05 | -438.72 | -523.74 | -657.91 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 08:56:25 · For reference only, not investment advice and not tailored to your situation.